EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characteristics and treatment patterns in patients with multiple myeloma in Japan: A retrospective cohort analysis

Shinsuke Iida, Yusuke Yasutomi iD, Yevgeniy Samyshkin iD, Yi-Chen Chen, Chi-Chang Chen, Wen Shi Lee, Seok-Won Kim iD, Catherine McGuiness, Zifan Zhou iD, Simon McNamara

PLOS ONE · 23.01.2025 · 20 (1) · e0315932

DOI: 10.1371/journal.pone.0315932 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 23.01.2025. Verfasst von Shinsuke Iida und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Approval of proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies (mAbs), such as daratumumab, has reshaped treatment patterns in patients with multiple myeloma (MM) in Japan. This retrospective study evaluated patient characteristics, treatment patterns, and trends in MM patients using Medical Data Vision, the largest electronic health records database in Japan with anonymous inpatient and outpatient health information.

Methods

Patients aged ≥18 years, with ≥2 records of an MM diagnostic and disease code and ≥1 record of MM treatment between 01 April 2008 and 30 June 2023 were included. Patients starting first-line (1L) treatment on or after 01 January 2020 were categorized into the 1+L cohort; those starting second-line (2L) treatment on or after 01 January 2018 were allocated to the 2+L cohort.

Results

Within the study period, 21,066 patients had an MM diagnosis, including 6,337 and 5,964 patients in the 1+L and 2+L cohorts, respectively. Median age was 74 years in both cohorts and gender distribution was similar (52.4% and 51.3% males, respectively). In the 1+L cohort, most patients (5,754/6,337; 90.8%) did not receive transplant, among whom 51.0% received 1L lenalidomide-based therapy, primarily daratumumab/lenalidomide/dexamethasone (DRd; 15.0%) or lenalidomide/dexamethasone (Rd;14.0%). In non-transplant patients, 1L DRd use increased from 6.0% in January–June 2020 to 28.0% in January–June 2023. In the 2+L cohort, 2L lenalidomide-based therapy use decreased from 65.0% in January–June 2018 to 37.0% in January–June 2023; daratumumab-based therapy increased from 14.0% to 39.0%. Retreatment with lenalidomide-, daratumumab-, and isatuximab-based therapy occurred in 44.1%, 35.2%, and 5.6% of patients, respectively.

Conclusion

The high use of lenalidomide and DRd in 1L, and high rates of retreatment with lenalidomide and anti-CD38 mAbs in 2L+ indicate a substantial need for new treatment modalities that can be used in 2L+ patients who previously received lenalidomide with/without an anti-CD38 mAb therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleAgedRetrospective StudiesJapanMiddle AgedAged, 80 and overAntibodies, MonoclonalLenalidomideAdultDexamethasone

Substanzen

daratumumabAntibodies, MonoclonalLenalidomideDexamethasone

Autor:innen und Institutionen

  • Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • GSK Tokyo, Tokyo, Japan.
  • GSK London, London, United Kingdom.
  • GSK Singapore, Singapore, Singapore.
  • IQVIA, Wayne, Pennsylvania, United States of America.
  • IQVIA Solutions Japan G.K., Tokyo, Japan.

ORCID-Profile: Yusuke Yasutomi, Yevgeniy Samyshkin, Seok-Won Kim, Zifan Zhou

Förderung

  • GlaxoSmithKline Japan

Zitieren

APA

Iida, S., Yasutomi, Y., Samyshkin, Y., Chen, Y. C., Chen, C. C., Lee, W. S., Kim, S. W., McGuiness, C., Zhou, Z., & McNamara, S. (2025). Characteristics and treatment patterns in patients with multiple myeloma in Japan: A retrospective cohort analysis. PLOS ONE, 20(1), e0315932. https://doi.org/10.1371/journal.pone.0315932

Vancouver

Iida S, Yasutomi Y, Samyshkin Y, Chen YC, Chen CC, Lee WS, et al. Characteristics and treatment patterns in patients with multiple myeloma in Japan: A retrospective cohort analysis. PLOS ONE. 2025;20(1):e0315932. doi:10.1371/journal.pone.0315932

BibTeX
@article{Iida2025,
  author = {Iida, Shinsuke and Yasutomi, Yusuke and Samyshkin, Yevgeniy and Chen, Yi-Chen and Chen, Chi-Chang and Lee, Wen Shi and Kim, Seok-Won and McGuiness, Catherine and Zhou, Zifan and McNamara, Simon},
  title = {Characteristics and treatment patterns in patients with multiple myeloma in Japan: A retrospective cohort analysis},
  journal = {PLOS ONE},
  year = {2025},
  volume = {20},
  number = {1},
  pages = {e0315932},
  doi = {10.1371/journal.pone.0315932}
}
Kostenlos starten →